| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.649 | 14.296 | 16.706 | 21.072 | 29.452 | 26.370 | 26.210 | 30.383 | 17.640 | 32.692 |
| Total Income - EUR | 8.649 | 14.298 | 16.707 | 21.057 | 29.452 | 26.370 | 26.210 | 30.383 | 17.599 | 51.730 |
| Total Expenses - EUR | 14.329 | 8.872 | 10.556 | 10.814 | 14.529 | 15.042 | 23.495 | 23.347 | 34.194 | 52.108 |
| Gross Profit/Loss - EUR | -5.680 | 5.426 | 6.151 | 10.243 | 14.924 | 11.328 | 2.715 | 7.036 | -16.596 | -378 |
| Net Profit/Loss - EUR | -5.939 | 5.141 | 5.984 | 10.032 | 14.629 | 11.076 | 2.485 | 6.766 | -16.763 | -1.899 |
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Endocrinologie - Office Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 90 | 0 | 0 | 0 | 0 | 29.882 | 24.907 | 17.297 | 21.644 | 45.864 |
| Current Assets | 1.718 | 625 | 2.646 | 4.254 | 18.754 | 28.003 | 25.025 | 35.899 | 10.334 | 1.030 |
| Inventories | 0 | 0 | 131 | 0 | 0 | 0 | 65 | 0 | 51 | 0 |
| Receivables | 385 | 373 | 1.880 | 3.835 | 1.926 | 3.978 | 400 | 326 | 603 | 0 |
| Cash | 1.333 | 251 | 635 | 419 | 16.828 | 24.025 | 24.560 | 35.573 | 9.680 | 1.030 |
| Shareholders Funds | -20.088 | -14.742 | -8.509 | 1.680 | 16.276 | 27.044 | 28.929 | 35.785 | 5.753 | 3.821 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 21.895 | 15.367 | 11.155 | 2.574 | 2.478 | 30.841 | 21.002 | 17.411 | 26.224 | 43.073 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endocrinologie - Office Srl